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Results of RESONATE-2 (PCYC-1115/1116) supported approval ofibrutinib for first-line treatment of chronic lymphocyticleukemia. Extended analysis of RESONATE-2 was conducted to
determine long-term efficacy and safety of ibrutinib in older patients
with chronic lymphocytic leukemia. A total of 269 patients aged ≥65
years with previously untreated chronic lymphocytic leukemia with-
out del(17p) were randomized 1:1 to ibrutinib (n=136) or chlorambucil
(n=133) on days 1 and 15 of a 28-day cycle for 12 cycles. Median ibru-
tinib treatment duration was 28.5 months. Ibrutinib significantly pro-
longed progression-free survival versus chlorambucil (median, not
reached vs. 15 months; hazard ratio, 0.12; 95% confidence interval,
0.07-0.20; P<0.0001). The 24-month progression-free survival was
89% with ibrutinib (97% and 89% in patients with del[11q] and
unmutated immunoglobulin heavy chain variable region gene, respec-
tively). Progression-free survival rates at 24 months were also similar
regardless of age (<75 years [88%], ≥75 years [89%]). Overall response
rate was 92% (125/136). Rate of complete response increased substan-
tially from 7% at 12 months to 18% with extended follow up. Greater
quality of life improvements occurred with ibrutinib versus chlorambu-
cil in Functional Assessment of Chronic Illness Therapy-Fatigue
(P=0.0013). The most frequent grade ≥3 adverse events were neutrope-
nia (12%), anemia (7%), and hypertension (5%). Rate of discontinua-
tions due to adverse events was 12%. Results demonstrated that first-
line ibrutinib for elderly patients with chronic lymphocytic leukemia
provides sustained response and progression-free survival benefits over
chemotherapy, with depth of response improving over time without
new toxicity concerns. This trial was registered at clinicaltrials.gov iden-
tifier 01722487 and 01724346.   
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) is the most com-
mon leukemia in Western countries and is increasing in
prevalence with the prolonged survival observed with
introduction of novel combinations and targeted treat-
ments such as ibrutinib.1 With a median age at diagnosis
of 71 years,1 management of this predominately older
population is controversial given that frequent comorbidi-
ties often preclude aggressive therapy. Randomized stud-
ies have provided disparate results in older compared with
younger patients.2,3 Less intensive approaches, such as
chlorambucil, provide limited response durability. While
the addition of anti-CD20 antibodies has improved out-
comes achieved with single-agent chlorambucil, adminis-
tration of these intravenous agents has associated toxicity,
and response durations remain limited.4
The first-in-class, oral, once-daily, Bruton’s tyrosine
kinase (BTK) inhibitor ibrutinib targets signaling via the 
B-cell receptor cascade, critical to survival of malignant
lymphocytes.5-9 Ibrutinib demonstrated tolerability, a high
rate of objective responses, and prolongation of progres-
sion-free survival and overall survival in patients with
relapsed/refractory CLL.10 Early-phase studies demonstrat-
ed responses of up to 84% in previously untreated
patients, with complete response (CR) rates of up to 23%
and up to 3 years of median follow up.11,12 This small
cohort suggested that single-agent ibrutinib might provide
durable efficacy in first-line treatment of patients with
CLL while avoiding toxicity inherent to cytotoxic or other
infused regimens. 
RESONATE-2 was an international phase 3 study
designed to definitively evaluate first-line ibrutinib treat-
ment in older patients who often had baseline frailties
against a standard chemotherapeutic agent, chlorambu-
cil.13 Primary results demonstrated an 84% reduction in
the risk of death at a median follow up of 18 months for
ibrutinib compared with chlorambucil. Based on these
findings, ibrutinib received approval in the United States,
Europe, and other regions for the first-line treatment of
patients with CLL, and allows for treatment without
chemotherapy.14,15 A detailed analysis of overall survival
(OS) with longer follow up and adjustment for the impact
of treatment crossover was previously reported.16 A sepa-
rate data cut was subsequently performed after this
detailed OS analysis to evaluate additional outcomes after
long-term follow up. Herein, we present the extended
analysis of additional outcomes from RESONATE-2
including quality-of-life (QOL) measures that may help
guide appropriate use of ibrutinib for previously untreated
patients. 
Methods
Study design and population
Eligible patients for RESONATE-2 (PCYC-1115/1116; clinicaltri-
als.gov identifier 01722487/01724346) had previously untreated CLL
or SLL with active disease and were ≥65 years. Patients ≤70 years
of age must have had a comorbidity that precluded treatment with
fludarabine-cyclophosphamide-rituximab. Eligible patients had an
Eastern Cooperative Oncology Group (ECOG) performance status
≤2, absolute neutrophil count ≥1000 cells/mm3, platelet count
≥50,000/mm3, and adequate liver and kidney function. Those with
del(17p) CLL were excluded.
This study was conducted according to principles of the
Declaration of Helsinki and the International Conference on
Harmonisation Guidelines for Good Clinical Practice and
approved by the institutional review boards of participating insti-
tutions. All patients provided written informed consent.
Patients were randomly assigned in a 1:1 ratio to treatment with
oral ibrutinib, 420 mg once daily until disease progression or chlo-
rambucil, 0.5 mg/kg (increased up to 0.8 mg/kg based on tolerabil-
ity) on days 1 and 15 of a 28-day cycle for 12 cycles. Patients from
the chlorambucil treatment arm with independent review com-
mittee (IRC)-confirmed disease progression were eligible to cross
over to second-line treatment with ibrutinib at the investigator’s
discretion.
End points and assessments
End points included progression-free survival (PFS, defined as
time from randomization to progression or death, whichever
occurs earlier), overall survival (OS), overall response rate (ORR),
improvement in hematologic variables, patient-reported health-
related QOL, and safety. Disease progression and response was
determined by investigator. QOL was assessed using the
Functional Assessment of Chronic Illness Therapy (FACIT)-
Fatigue questionnaires. Safety assessments included adverse
events (AEs) and laboratory parameters. Non-hematologic AEs
were graded using Common Terminology Criteria for Adverse
Events, v4.03. Hematologic AEs were graded using International
Workshop on CLL criteria.17
Statistical analyses
PFS and OS were analyzed using Kaplan-Meier estimates and a
2-sided log-rank test stratified by the randomization factors.
Sensitivity analyses were performed to adjust for the impact of
crossover on OS as previously described.16 ORR was analyzed
with the Cochran-Mantel-Haenszel c2 test, stratified by the ran-
domization factors. QOL analyses were based on the proportion
of patients with clinically meaningful changes in scores from base-
line (≥3 points for FACIT-Fatigue). Additional QOL analyses used
time-dependent mixed-models repeated measures analysis.
Results
Patients
There were 269 patients randomly assigned to ibrutinib
(n=136) or chlorambucil (n=133) monotherapy in the RES-
ONATE-2 study (Online Supplementary Figure S1).13 Patient
characteristics were well balanced across treatment arms,
as previously reported (Table 1).13 The median patient age
was 73 years on the ibrutinib arm and 72 years on the
chlorambucil arm. In the ibrutinib treatment arm, of those
evaluated, 22% (29/130) had del(11q), and 48% (58/121)
had unmutated IGHV. Patients initiated ibrutinib treat-
ment for active disease per iwCLL criteria, most common-
ly manifesting as marrow failure (progressive anemia or
thrombocytopenia [40%]), progressive or symptomatic
lymphadenopathy (40%) or splenomegaly (26%), with
many patients having more than one indication for treat-
ment including disease symptoms such as fatigue or night
sweats (Table 1). Although 32% of patients had substan-
tial fatigue when entering study, only 5% were started on
CLL treatment solely for fatigue that was considered to
have interfered with work or usual activities. With a medi-
an follow up for this extended analysis of 29 months
(maximum, 36 months), 107 patients (79%) remain on
first-line ibrutinib.
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Survival outcomes
Ibrutinib resulted in significantly longer PFS compared
with chlorambucil (median, PFS not reached vs. 15.0
months; Figure 1A). There was an 88% reduction in risk
of PFS events (progression or death; hazard ratio [HR],
0.12; 95% CI, 0.07-0.20; P<0.0001) for patients random-
ized to ibrutinib. PFS at 24 months was 89% with ibruti-
nib versus 34% with chlorambucil. This rate was relatively
stable with ibrutinib with an 18-month PFS of 94%.
Ibrutinib consistently demonstrated significant improve-
ments in PFS for patients in all subgroups including those
considered high risk (Figure 2). In patients treated with
ibrutinib, only 1 patient with del(11q) has had disease pro-
gression, and the rates of 24-month PFS were 97% and
86% for those with or without del(11q), respectively
(Figure 1B). No significant difference was observed in the
PFS of patients with unmutated versusmutated IGHV (24-
month PFS, 90% and 89%, respectively; Figure 1C). PFS
benefits were consistent across additional subgroups of
patients, including those with advanced disease (Rai stage
3 or 4) or bulky disease (Figure 2). PFS and OS rates were
also similar regardless of age (24-month PFS, <75 years
[88%], ≥75 years [89%]; OS, <75 years [94%], ≥75 years
[96%]; Figure S2). With longer follow up and despite
patient crossover, ibrutinib continues to demonstrate an
OS benefit compared with chlorambucil (HR, 0.43; 95%
CI, 0.21-0.86; P=0.0145; Online Supplementary Figure S3
and Table S1), with a 24-month OS of 95% for ibrutinib vs.
84% for chlorambucil (Online Supplementary Figure S3). 
Responses for ibrutinib-treated patients
With a maximum of 36 months of follow up, the ORR
with ibrutinib treatment was 92% (Table 2). Eighteen per-
cent of patients achieved CR, which improved from 7% at
12 months and 15% at 24 months (Figure 3). Comparable
ORR and CR rates were also observed in high-risk sub-
groups, including those with del(11q) (ORR, 100%; CR
rate, 14%) or unmutated IGHV (ORR, 95%; CR rate,
21%). 
Disease burden and symptoms
The vast majority of ibrutinib-treated patients experi-
enced substantial reduction in lymphadenopathy and
splenomegaly at the time of the primary analysis which
was much greater than observed with chlorambucil. A
≥50% reduction in the lymph node sum of the product of
longest diameter (SPD) occurred in 95% of patients treat-
ed with ibrutinib versus 40% of those treated with chlo-
rambucil, with complete resolution in lymphadenopathy
in 42% versus 7%, respectively (Online Supplementary
Figure S4A,B). Reduction in splenomegaly by ≥50%
occurred in 95% with ibrutinib versus 52% with chloram-
bucil, with complete resolution in splenomegaly in 56%
versus 22%, respectively (Online Supplementary Figure
S4C,D). Ibrutinib also resulted in higher rates of improve-
ments in disease symptoms including weight loss, fatigue,
and night sweats, which were indications for therapy in
many patients.
Patient-reported QOL
Greater improvements in QOL occurred with ibrutinib
versus chlorambucil in FACIT-Fatigue (P=0.0013) by
repeated measure analyses (Online Supplementary Figure
S5). Clinically meaningful improvements occurred more
frequently with ibrutinib versus chlorambucil in FACIT-
Fatigue, although this was not statistically significant
(86/136 [63%] vs. 71/133 [53%]; odds ratio, 1.50; 95% CI,
0.92-2.45; P=0.1013).
Safety and tolerability of ibrutinib
Median treatment duration with ibrutinib was 28.5
months (range, 0.7-35.9 months). Most patients continue
ibrutinib treatment, with 83% (112/135) receiving ibruti-
nib continuously for durations exceeding 2 years. The
most frequent AEs with ibrutinib with extended follow up
were similar to the primary report13: diarrhea, fatigue,
P.M. Barr et al.
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Table 1. RESONATE-2 reasons for initiation of treatment and baseline
patient characteristics.1
Ibrutinib Chlorambucil
(n=136) (n=133)
Baseline Characteristic
Median age (range), y 73 (65-89) 72 (65-90)
≥ 75 y, (%) 46 (34) 47 (35)
Male, n (%) 88 (65) 81 (61)
ECOG performance status, n (%)
0 60 (44) 54 (41)
1 65 (48) 67 (50)
2 11 (8) 12 (9)
Rai stage III or IV, n (%) 60 (44) 62 (47)
Bulky disease ≥ 5 cm, n (%) 54 (40) 40 (30)
Hierarchical Classificationa, n (%)
Del(11q) 29/130 (22) 25/121 (21)
Trisomy 12 20/117 (17) 23/108 (21)
Del(13q) 25/112 (22) 32/108 (30)
None of above 38/112 (34) 28/108 (26)
IGHV statusb, n/N (%)
Mutated 40/121 (33) 42/127 (33)
Unmutated 58/121 (48) 60/127 (47)
Unclassifiablec 23/121 (19) 25/127 (20)
Patients meeting criteria for active disease, n (%)
Progressive marrow failure 54 (40) 49 (37)
Lymphadenopathy 55 (40) 44 (33)
Splenomegaly 36 (26) 44 (33)
Progressive lymphocytosis 23 (17) 28 (21)
Autoimmune anemia and/or 3 (2) 5 (4)
thrombocytopenia
Any documented constitutional 64 (47) 56 (42)
symptoms
Unintentional weight loss 14 (10) 16 (12)
(>10% within 6 months)
Significant fatigue 44 (32) 29 (22)
Fever 4 (3) 3 (2)
Night sweats 32 (24) 35 (26)
ECOG: Eastern Cooperative Oncology Group; FISH: fluorescence in situ hybridization;
IGHV: immunoglobulin heavy-chain variable-region gene. aPatients with missing
results were excluded (Del(11): n=6 for ibrutinib, n=12 for chlorambucil; Trisomy 12:
n=19 for ibrutinib, n=25 for chlorambucil; Del(13q): n=24 for ibrutinib, n=25 for chlo-
rambucil; None of the above: n=24 for ibrutinib, n=25 for chlorambucil). bPatients with
missing results were excluded (n=15 for ibrutinib, n=6 for chlorambucil).
cUnclassifiable includes patients with polyclonal IGHV status if no specific IGHV sub-
family member was dominant (>50% of all reads) and samples with no amplification.
cough, anemia, and nausea (Online Supplementary Table
S2). Grade ≥3 AEs were generally observed more fre-
quently during the first 12 months of ibrutinib therapy
and generally decreased over time (Figure 4). Rates of
grade ≥3 cytopenias decreased over time from 8.1%,
5.9%, and 2.2% during the first year of treatment to 0%,
1%, and 0% during the third year of treatment for neu-
tropenia, anemia, and thrombocytopenia, respectively.
Several AEs of clinical interest were characterized in
greater detail (Table 3). Diarrhea generally occurred early
in treatment (median, 26 days) and was completely
reversible in 95% of patients within a median of 6 days.
Visual disturbances (blurred vision or reduced visual acu-
ity) were grade 1 or 2, with 57% of these completely
resolving within a median of 37.5 days after onset.
Hypertension occurred at a median of 187 days, with
improvements reported at a median of 14 days after onset.
Arthralgia was observed at a median of 135 days and was
generally reversible (78% complete, 4% partial) within a
median duration of approximately 3 weeks. Atrial fibrilla-
tion was observed throughout treatment follow up, with
4% of patients experiencing a grade 3 event. Symptoms of
atrial fibrillation quickly resolved in the majority of
patients (57% complete, 7% partial resolution) within a
median of 3 days. Nine patients (7%) experienced a major
hemorrhage occurring at a median of 310 days. Of these,
3 patients were reported to have active treatment with
concomitant medications that impact platelets or coagula-
tion (aspirin, low molecular weight heparin, and naprox-
en, respectively) including a traumatic hematoma, post-
procedural hematoma, and hematuria, all of which were
grade 3 in severity and did not result in study drug discon-
tinuation. Grade ≥3 infection occurred in 23% of patients
at a median of 138 days, including 2 that were fatal
(Klebsiella infection and septic shock). Grade ≥3 infections
were observed most frequently in the first year of treat-
ment and decreased thereafter (Figure 4). There were no
cases of pneumocystis pneumonia or multifocal leukoen-
Extended Phase 3 Results From RESONATE-2
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Figure 1. PFS for the intent-to-treat population. Survival analyses from ran-
domization until event or censored at last follow up using the Kaplan-Meier
method. Vertical ticks indicate censored patients. PFS: progression-free sur-
vival. 
A B
C PFS with mutated vs. unmutated IGHV
PFS in the presence or absence of Del(11q)PFS 
HR (95% CI)
P value
cephalopathy reported. 
Serious AEs over the 3 years of follow up occurring in
more than 2 ibrutinib-treated patients included pneumo-
nia (11; 8%), atrial fibrillation (6; 4%), urinary tract infec-
tion (5; 4%), basal cell carcinoma (5; 4%), hyponatremia
(5; 4%), pleural effusion (4; 3%), hypertension (3; 2%),
and anemia (3; 2%).
Eighteen patients (13%) required dose reductions and
16 patients (12%) discontinued first-line ibrutinib because
of AEs. AEs leading to discontinuation in more than 
1 patient included infection (n=5), hemorrhage (n=3), atri-
al fibrillation (n=2), and rash (n=2). Treatment-limiting
toxicity including both reductions and discontinuations
due to AEs decreased over time with ibrutinib (Figure 4).
Concomitant medications
Concomitant medications were collected throughout
the duration of ibrutinib treatment (median, 28.5 months)
and chlorambucil (median, 7.1 months). Despite longer
follow up recording of the use of these agents in the ibru-
tinib arm versus the chlorambucil arm, the rate of neu-
trophil growth factor use and platelet and red blood cell
transfusion was higher in the chlorambucil arm.
Intravenous immunoglobulin was administered to 4% of
ibrutinib-treated patients versus 2% of those randomized
to chlorambucil. Anticoagulants and/or antiplatelet agents
were frequently used during study therapy (56% and 54%
of patients treated with ibrutinib and chlorambucil,
respectively; Online Supplementary Table S3), including
anticoagulants in 21% of the ibrutinib-treated patients. 
Outcomes following ibrutinib discontinuation
With up to 3 years follow up, out of 136 patients, only
4 patients discontinued ibrutinib primarily due to disease
progression; 1 had unmutated IGHV and none were
reported to have del(11q). Two of these 4 patients remain
alive. Of the 16 patients who discontinued ibrutinib
because of AEs; 13 (81%) are alive with a median of 13
P.M. Barr et al.
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Figure 2. PFS subgroup analysis. 
Table 2. Response rates in ibrutinib-treated patients.
Best response, All patients With del(11q) Without del(11q) Mutated IGHV Unmutated IGHV
n (%) (n=136) (n=29) (n=101) (n=40) (n=58)
ORR 125 (92) 29 (100) 91 (90) 35 (88) 55 (95)
CR/CRi 25 (18) 4 (14) 20 (20) 8 (20) 12 (21)
nPR 1 (1) 0 1 (1) 3 (8) 0
PR 97 (71) 25 (86) 68 (67) 26 (65) 43 (74)
PR-L 2 (1) 0 2 (2) 0 0
Cri: complete response with incomplete blood-count recovery; nPR: nodular partial response (defined according to the International Workshop on Chronic Lymphocytic
Leukemia criteria for response16 as a complete response with lymphoid nodules in the bone marrow); PR: partial response; PR-L: partial response with lymphocytosis.
Sex
months follow up after ibrutinib discontinuation and 3
have died (Online Supplementary Table S4). Ten of the
patients had PR as best response, 4 patients discontinued
after not responding to ibrutinib and 2 patients discontin-
ued prior to response evaluation. Non-responders/non-
evaluable had a PFS that ranged from 1.8 to 20.2 months,
while responders tended to have a variable but longer PFS
(4.2–34.0 months). As the vast majority of patients (79%)
remain on single-agent ibrutinib, this analysis is limited in
size and also to the patients who came off treatment fairly
early (9 of the 16 patients who discontinued due to AEs
did so in the first year). In total, 7 patients received subse-
quent therapy after ibrutinib at a median of 7.6 months
following ibrutinib discontinuation (range, 1.2 to 
20.8 months), including fludarabine-cyclophosphamide-
rituximab (n=3), bendamustine-rituximab (n=2), chloram-
bucil (n=1), and radiation (n=1). Six of these 7 patients
(86%) remain alive with median follow up of 21 months
(range, 9 to 25 months). 
Discussion
This extended analysis of RESONATE-2 with detailed
clinical follow up demonstrates that ibrutinib continues to
provide significant and sustained clinical benefits, improv-
ing the quality of responses, for the first-line treatment of
older patients with CLL or SLL with a manageable safety
profile over extended durations of treatment. Consistent
with the initial report, ibrutinib demonstrates a significant
88% reduction in the risk of PFS events (progression or
death) compared with chlorambucil (P<0.0001) with
extended follow up. In addition, the OS benefit for ibruti-
nib compared with chlorambucil was maintained, despite
crossover to treatment with ibrutinib for many patients in
the chlorambucil arm (n=55). These data support the use
of ibrutinib in the first-line treatment of CLL as a
chemotherapy-free option that can be taken continuously,
achieving long-term disease control for the majority of
patients including those with high risk features.10,13
Ibrutinib has a category 1 National Comprehensive
Cancer Network® (NCCN®) recommendation as a single-
agent first-line treatment for CLL without del(17p) in
patients ≥65 years and for relapsed/refractory CLL with-
out del(17p).18
The efficacy of ibrutinib in the first-line setting appears
superior to that observed in relapsed or refractory
patients.19 Nearly all patients randomly assigned to ibruti-
nib achieved rapid disease reduction, with an ORR of
92% translating to high rates of 24-month PFS and OS of
89% and 95%, respectively, with similar PFS and OS rates
seen regardless of age. This observation suggests that ibru-
tinib may be most effective when used upfront before the
acquisition of poor-risk molecular aberrations, which are
selected for with chemotherapy.20,21 Additionally, sensitiv-
ity analyses to adjust for the effects of patients in RES-
ONATE-2 who crossed over to ibrutinib found that treat-
ment with ibrutinib was still associated with statically sig-
nificant OS compared with chlorambucil.16 These results
also demonstrate that depth of response substantially
increases over time, with higher rates of CR during the
extended follow up, indicating a persistent action of the
drug rather than a simple maintenance effect. Similar find-
ings were observed with long-term follow up of patients
enrolled in the phase 2 trial of first-line ibrutinib.11 Within
this previous study, 29% of patients achieved a CR, and
92% remained alive and progression free at 5 years.22
Given these data, the CR rate will likely continue to
increase in the present study as long-term disease control
and high tolerability with first-line use can be expected
based on the earlier phase 2 results.12 
In addition to the efficacy benefits overall, sustained
Extended Phase 3 Results From RESONATE-2
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Figure 3. Response rates over time in ibrutinib-treated patients. CR: complete response; CRi: complete response with incomplete blood-count recovery; nPR: nodular
partial response (defined according to the International Workshop on Chronic Lymphocytic Leukemia criteria for response16 as a complete response with lymphoid
nodules in the bone marrow); PR: partial response; PR-L: partial response with lymphocytosis.
robust outcomes were demonstrated in higher-risk
groups. No difference in outcome was observed in
patients with unmutated IGHV status, a traditional poor
prognostic indicator for all chemoimmunotherapy regi-
mens. Notably the rate of unmutated IGHV in this study
of older patients was somewhat lower than other studies
at 48% (vs. 58%-62% in CLL11), consistent with prior
reports of higher frequency of unmutated IGHV in
younger patients.4,23 For patients with del(11q), another
traditionally high-risk subgroup, 100% of the 29 patients
responded to treatment with ibrutinib, and there was a
99% reduction in the risk of progression or death, with
only 1 del(11q) ibrutinib-treated patient experiencing dis-
ease progression after discontinuing therapy for an AE
over the extended follow up. While this represents a rela-
tively small patient subset (22%), ibrutinib demonstrates a
particularly significant benefit in this population, which
historically experiences inferior outcomes with traditional
chemotherapy or CD20-based regimens.24-26 Combined
analysis of 3 randomized studies not only demonstrated
superiority of ibrutinib over traditional chemotherapy
and/or anti-CD20 comparators for patients with del(11q),
but also equally positive PFS and OS outcomes irrespec-
tive of del(11q). These results suggest that current defini-
tions of high-risk disease and the impact of prognostic bio-
markers may need to be redefined with ibrutinib.27 The
mechanism why del(11q) patients may have better out-
comes when treated with ibrutinib is of high interest and
is the subject of ongoing research.
Safety of therapy administered to older patients over
the long term is an area that requires close scrutiny. First-
line ibrutinib appears to be well tolerated with extended
treatment as evidenced by over 80% of this older popula-
tion being able to continue treatment for more than 2
P.M. Barr et al.
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Table 3. Characterization of select AEs of clinical interest in ibrutinib-treated patients observed at any time during follow up.a
Ibrutinib-treated patients 
n=135 Resolution, Median time to first event, Median time from onset to
AE n (%) n (%) days resolution/improvement, days
Grade Any 2 3 4 5 Complete Partial Any 2 3 4 5 Any 2 3 4
Diarrhea 61 (45) 16 (12) 5 (4) 0 0 58 (95) 0 26 131 219 NA NA 6 3 6.5 NA
Visual disturbancesb 30 (22) 6 (4) 0 0 0 17 (57) 0 100 201 NA NA NA 37.5 74.5 NA NA
Hypertensionc 27 (20) 13 (10) 7 (5) 0 0 12 (44) 1 (4) 187 187 109.5 NA NA 14 36 9 NA
Arthralgia 27 (20) 9 (7) 3 (2) 0 0 21 (78) 1 (4) 135 55 135 NA NA 22 22 15 NA
Atrial fibrillation 14 (10) 7 (5) 6 (4) 0 0 8 (57) 1 (7) 249.5 85 773.5 NA NA 3 2 7 NA
Major hemorrhage 9 (7) 1 7 (5) 1 (1) 0 9 (100) 0 310 155 446 254 NA 13.5 14.0 11.0 45.0
(<1)
Infections (grade ≥3) 31 (23) NA 28 (21) 4 (3) 2 (1) 28 (90) 0 138 NA 119 367.5 422 9 NA 9 16
AE: adverse event; NA: not applicable. aFrom first dose of study treatment up to 30 days after last dose or initiation of subsequent anti-cancer therapy, whichever occurs earlier 
bVisual disturbances included the preferred terms blurred vision and reduced visual acuity. cHypertension (standardized MEDRA queries) group of preferred terms.
.
Figure 4. Safety and tolera-
bility of ibrutinib over time.
Rate of grade ≥3 AEs, dis-
continuations due to AEs,
and dose reductions over dif-
ferent periods of time.  AE,
adverse events.
(n=135)
(n=123)
(n=112)
years. This extended follow up allowed for new observa-
tions into the timing of when AEs occurred and time to
resolution of AEs as well as the use of transfusions and
growth factors. Diarrhea, while frequent, often occurred
early during the first several months of treatment and was
generally low grade and short-lived. Severe and treatment-
limiting AE rates decreased over time with extended ibru-
tinib treatment. A decrease in myelotoxicity and infec-
tious complications over time was also observed. This
contrasts with chemoimmunotherapy-associated AEs and
was importantly associated with less medical resource uti-
lization of neutrophil growth factors and slightly less
transfusion need despite 4 times the treatment time with
ibrutinib. While the rate of atrial fibrillation increased
from 6% in the primary analysis13 to 10%, overall, ibruti-
nib dose reduction or discontinuation due to atrial fibrilla-
tion was uncommon and lessened with extended treat-
ment in this population of older patients with CLL. Atrial
fibrillation therefore appears manageable and does not fre-
quently necessitate ibrutinib discontinuation.  Additional
information on the management and outcomes of atrial
fibrillation along with associated anticoagulant therapy
has been provided in a large pooled analysis of ibrutinib
studies.28 Rates of major hemorrhage remained low
despite half the patients receiving concomitant antiplatelet
or anticoagulant medications. 
Previous work demonstrated that QOL is significantly
compromised in patients with CLL, affecting physical fit-
ness, cognitive function, levels of fatigue, and sleep. Worse
scores were reported for patients receiving chemotherapy
such as chlorambucil.29 Even with the addition of contem-
porary anti-CD20 agents (obinutuzumab), no significant
benefit in QOL has been noted.4 However, this extended
follow up provides the first analysis of QOL, as measured
by FACIT Fatigue Scale, following ibrutinib treatment in
previously untreated patients. Significantly greater
improvements in QOL were observed with ibrutinib versus
chlorambucil. In line with this and the favorable impact on
QOL and tolerable safety profile, 79% of patients remained
on first-line treatment with ibrutinib at the time of this later
analysis with up to 3 years of therapy.
Patients who discontinue treatment for CLL including
ibrutinib may have varied outcomes dependent on the
reason for discontinuation.30 In 1 study that included most-
ly patients with relapsed or refractory CLL, median OS
following ibrutinib therapy was 33 months for those who
discontinued because of AEs versus 16 months for those
who discontinued because of disease progression. In our
study, the 22 patients who discontinued therapy had a
median follow up of 13 months after discontinuation. Of
these 22 patients, 16 are still alive, while 2 of the 4 patients
who progressed have died. Seven patients have received
subsequent treatment, mostly chemoimmunotherapy (BR,
FCR); 6 of those patients are still alive, with a median of
21 months of follow up. While retrospective analyses of
real-world data have previously suggested that treatment
with an alternate kinase inhibitor is more effective than
chemoimmunotherapy following discontinuation of ibru-
tinib,31,32 our data suggests that patients who discontinue
ibrutinib can respond to chemoimmunotherapy as sec-
ond-line therapy. Continued follow up of patients in the
RESONATE-2 trial who have discontinued ibrutinib will
provide the needed further data as relatively few patients
have progressed or stopped therapy to date.  
These data confirm that first-line treatment with ibruti-
nib results in long-term PFS in patients with CLL and that
response quality continues to improve with ibrutinib over
time, with substantial increase in patients achieving CR.
In addition, rates of grade ≥3 AEs during treatment with
ibrutinib decreased over time. The most common reasons
for initiating first-line treatment in these patients, includ-
ing marrow failure, disease burden, and disease symp-
toms, all improved to greater extents in patients treated
with ibrutinib versus chemotherapy. Ongoing randomized
studies, including ILLUMINATE (clinicaltrials.gov identifier
02264574), comparing ibrutinib-obinutuzumab with chlo-
rambucil-obinutuzumab, and A041202 (clinicaltrials.gov
identifier 01886872), comparing ibrutinib, ibrutinib-ritux-
imab, and rituximab-bendamustine, will continue to
define the role of ibrutinib for the first-line treatment of
patients with CLL/SLL.
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